StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
86
This year
9
Publishing Date
2024 - 01 - 16
2
2023 - 10 - 31
1
2023 - 10 - 30
2
2023 - 10 - 25
1
2023 - 10 - 16
1
2023 - 10 - 09
1
2023 - 09 - 21
1
2023 - 09 - 14
1
2023 - 09 - 07
1
2023 - 09 - 06
1
2023 - 09 - 05
1
2023 - 08 - 14
1
2023 - 08 - 10
1
2023 - 07 - 19
1
2023 - 07 - 06
1
2023 - 06 - 30
1
2023 - 06 - 29
1
2023 - 06 - 19
1
2023 - 06 - 16
1
2023 - 06 - 02
1
2023 - 05 - 11
1
2023 - 05 - 08
2
2023 - 05 - 03
1
2023 - 04 - 20
1
2023 - 04 - 18
1
2023 - 04 - 17
1
2023 - 03 - 02
2
2023 - 02 - 28
1
2023 - 02 - 23
1
2023 - 02 - 15
1
2023 - 01 - 16
1
2023 - 01 - 10
1
2023 - 01 - 09
2
2022 - 12 - 14
1
2022 - 12 - 05
1
2022 - 12 - 02
1
2022 - 11 - 16
1
2022 - 11 - 15
1
2022 - 11 - 14
1
2022 - 11 - 07
1
2022 - 10 - 31
2
2022 - 10 - 05
1
2022 - 09 - 29
1
2022 - 09 - 26
1
2022 - 09 - 21
1
2022 - 09 - 16
1
2022 - 09 - 15
2
2022 - 09 - 13
1
2022 - 09 - 08
2
2022 - 08 - 29
1
2022 - 08 - 24
1
2022 - 08 - 23
1
2022 - 08 - 18
2
2022 - 08 - 10
1
2022 - 08 - 08
1
2022 - 08 - 03
1
2022 - 08 - 01
1
2022 - 07 - 27
1
2022 - 07 - 20
1
2022 - 07 - 18
1
Sector
Communications
2
Health technology
86
Manufacturing
4
N/a
1
Technology services
1
Tags
Acquisition
80
Alliances
71
America
64
Antibody
48
Approval
63
Approved
41
Biopharma
80
Biotech
49
Biotechnology
104
Business
80
Cancer
165
Children
61
Clinical-trials-phase-ii
42
Clinical-trials-phase-iii
67
Collaboration
80
Companies
59
Conference
48
Covid
43
Covid-19
75
Deal
50
Disease
130
Drug
173
Dupixent
105
Earnings
72
Europe
72
Events
54
Expected
44
Fda
204
Fda-approvals
43
Financial
163
Genetown
59
Global
356
Growing
50
Growth
280
Health
67
Market
710
Money
57
N/a
2232
News
96
People
161
Pharm-country
42
Pharma
145
Pharmaceutical
120
Positive
79
Potential
59
Reach
49
Regulatory
54
Report
306
Research
232
Results
291
Sanofi
198
Spac
46
Study
86
Therapeutics
320
Therapy
79
Treatment
227
Trial
120
Update
91
Vaccine
163
Year
61
Entities
10x genomics, inc.
1
Abbvie inc.
1
Acadia pharmaceuticals inc.
1
Adverum biotechnologies, inc.
1
Algernon pharmaceuticals inc.
1
Alnylam pharmaceuticals, inc.
11
Applied genetic technologies corporation
1
Arcus biosciences, inc.
1
Astellas pharma inc
1
Astrazeneca plc
1
Athenex, inc.
1
Atreca, inc.
1
Avid technology, inc.
1
Axsome therapeutics, inc.
1
Bausch health companies inc.
1
Biontech se
3
Bristol-myers squibb company
1
Calliditas therapeutics ab
1
Catalyst pharmaceuticals, inc.
1
Cellectis s.a.
1
Cti biopharma corp.
1
Curis, inc.
1
Cytodyn inc.
1
Eli lilly and company
37
Glaxosmithkline plc
1
I-mab
1
Icon plc
2
Immunogen, inc.
1
Incyte corporation
27
Inmed pharmaceuticals inc.
1
Innate pharma s.a.
3
Innate pharma sa
3
Intellia therapeutics, inc.
1
Johnson & johnson
8
Krystal biotech, inc.
1
Leap therapeutics, inc.
1
Merus n.v.
1
Mesoblast limited
1
Mitsubishi chemical holdings corp
1
Moderna, inc.
1
Novartis ag
1
Novo nordisk a/s
2
Onconova therapeutics, inc.
1
Orange
2
Pfizer, inc.
4
Pliant therapeutics, inc.
1
Provention bio, inc.
1
Regeneron pharmaceuticals, inc.
4
Regenxbio inc.
2
Repligen corporation
1
Sanofi
86
Silence therapeutics plc
1
Supernus pharmaceuticals, inc.
1
Teva pharmaceutical industries ltd
4
Trinity biotech plc
1
Ucb s.a.
1
Vbi vaccines, inc.
1
Vertex pharmaceuticals incorporated
2
Xencor, inc.
1
Symbols
ABVC
13
AGNPF
11
AKRO
11
ALGS
10
ALNY
12
ALPMF
14
ALPMY
14
ALVO
10
ANVS
9
ARVL
14
ARWR
13
ATHE
9
BBIO
13
BGNE
9
BIIB
14
BMEA
17
BMY
9
CGTX
13
CLDX
10
CNSP
10
CSCO
13
DARE
19
ELOX
10
EVOTF
9
FNCTF
43
GILD
11
HRMY
10
INCY
37
IONS
19
JNJ
67
KMDA
9
KPRX
9
LGND
13
LLY
74
LPTX
11
LTUM
9
MASI
15
MBOT
9
MDNA
14
MDT
16
MDWD
10
MS
11
NBIX
11
NTLA
10
NTRA
10
NVS
17
NVSEF
15
PCVX
11
PFE
20
PPRUF
14
PPRUY
14
PTN
10
SEEL
10
SILO
14
SILOD
14
SNY
86
SNYNF
86
STRO
14
TEVJF
20
TNXP
24
Exchanges
Nasdaq
86
Nyse
48
Crawled Date
2024 - 01 - 16
2
2023 - 10 - 31
1
2023 - 10 - 30
2
2023 - 10 - 25
1
2023 - 10 - 16
1
2023 - 10 - 09
1
2023 - 09 - 21
1
2023 - 09 - 14
1
2023 - 09 - 07
1
2023 - 09 - 06
1
2023 - 09 - 05
1
2023 - 08 - 14
1
2023 - 08 - 10
1
2023 - 07 - 19
1
2023 - 07 - 06
1
2023 - 06 - 30
1
2023 - 06 - 29
1
2023 - 06 - 19
1
2023 - 06 - 16
1
2023 - 06 - 02
1
2023 - 05 - 11
1
2023 - 05 - 08
2
2023 - 05 - 03
1
2023 - 04 - 20
1
2023 - 04 - 18
1
2023 - 04 - 17
1
2023 - 03 - 02
2
2023 - 02 - 28
1
2023 - 02 - 23
1
2023 - 02 - 15
1
2023 - 01 - 16
1
2023 - 01 - 10
1
2023 - 01 - 09
2
2022 - 12 - 14
1
2022 - 12 - 05
1
2022 - 12 - 02
1
2022 - 11 - 17
1
2022 - 11 - 15
1
2022 - 11 - 14
1
2022 - 11 - 07
1
2022 - 10 - 31
2
2022 - 10 - 05
1
2022 - 09 - 29
1
2022 - 09 - 26
1
2022 - 09 - 21
1
2022 - 09 - 16
1
2022 - 09 - 15
2
2022 - 09 - 13
1
2022 - 09 - 08
2
2022 - 08 - 29
1
2022 - 08 - 24
1
2022 - 08 - 23
1
2022 - 08 - 18
2
2022 - 08 - 10
1
2022 - 08 - 08
1
2022 - 08 - 03
1
2022 - 08 - 01
1
2022 - 07 - 27
1
2022 - 07 - 20
1
2022 - 07 - 18
1
Crawled Time
00:00
11
01:00
16
06:00
1
07:00
2
08:00
2
09:00
2
10:00
2
11:00
1
12:00
6
12:20
3
13:00
3
13:30
1
14:00
1
14:30
1
15:20
2
16:00
5
17:00
1
18:00
4
19:00
1
20:00
1
21:00
7
22:00
10
23:00
3
Source
www.algernonpharmaceuticals.com
1
www.biospace.com
27
www.globenewswire.com
3
www.prnewswire.com
54
www.vbivaccines.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Study
symbols :
Snynf
save search
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published:
2024-03-27
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-7.26%
|
O:
-0.26%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
-3.11%
|
O:
0.49%
H:
0.84%
C:
-0.07%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-6.28%
|
O:
1.06%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-6.77%
|
O:
-0.09%
H:
1.42%
C:
1.1%
ibi310
first
cancer
colon
therapy
study
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Published:
2024-03-06
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-1.01%
|
O:
0.0%
H:
0.8%
C:
0.8%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-3.03%
|
O:
-0.45%
H:
0.0%
C:
0.0%
IPHA
|
$2.35
-9.27%
-10.21%
16K
|
Health Technology
|
-6.23%
|
O:
0.78%
H:
1.93%
C:
0.97%
iph6501
first
study
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published:
2024-03-05
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-1.89%
|
O:
1.17%
H:
0.0%
C:
0.0%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-2.21%
|
O:
-0.73%
H:
1.52%
C:
0.5%
positive
blood
care
topline
results
study
Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy
Published:
2024-03-04
(Crawled : 18:00)
- biospace.com/
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-1.9%
|
O:
-0.9%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-2.68%
|
O:
-0.8%
H:
0.0%
C:
0.0%
opl-0401
health
treatment
study
diabetic
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
Published:
2024-03-01
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-2.32%
|
O:
0.01%
H:
0.0%
C:
-0.43%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-3.92%
|
O:
-1.27%
H:
0.0%
C:
0.0%
ibi3002
first
australia
study
Global mRNA-based Vaccines and Therapeutics Market is Projected to Grow Immensely During the Study Period (2019-2032) | DelveInsight
Published:
2024-01-25
(Crawled : 23:00)
- prnewswire.com
MTLHY
|
$29.93
-11.69%
1.1K
|
n/a
|
-2.09%
|
O:
-1.11%
H:
0.1%
C:
0.1%
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-6.6%
|
O:
1.8%
H:
0.0%
C:
-1.82%
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
-8.57%
|
O:
0.25%
H:
0.27%
C:
-0.2%
SLN
|
$21.575
1.53%
1.51%
120K
|
Health Technology
|
13.47%
|
O:
4.32%
H:
0.0%
C:
-3.68%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-7.6%
|
O:
0.5%
H:
0.0%
C:
0.0%
MRNA
|
News
S
|
$103.45
-0.33%
-0.33%
2M
|
Health Technology
|
0.61%
|
O:
0.72%
H:
0.34%
C:
-1.68%
MRUS
|
$41.01
1.74%
1.71%
410K
|
Health Technology
|
20.38%
|
O:
0.35%
H:
2.81%
C:
-0.53%
ICLR
|
$291.85
-0.74%
-0.75%
390K
|
Health Technology
|
9.99%
|
O:
1.13%
H:
0.82%
C:
-0.74%
BNTX
|
$86.42
0.09%
0.09%
1.2M
|
Health Technology
|
-10.9%
|
O:
-1.35%
H:
0.12%
C:
-0.83%
global
therapeutics
study
market
AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published:
2024-01-16
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-10.78%
|
O:
-1.83%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
18.31%
|
O:
0.77%
H:
0.17%
C:
-1.65%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-10.76%
|
O:
0.45%
H:
0.06%
C:
-0.5%
RGNX
|
News
|
$17.01
-2.8%
-2.88%
410K
|
Health Technology
|
11.53%
|
O:
-0.13%
H:
0.0%
C:
-7.15%
ADVM
|
$11.32
-2.5%
-2.56%
68K
|
Health Technology
|
1338.66%
|
O:
-0.69%
H:
2.32%
C:
-0.12%
therapy
growth
study
market
Sjogren's Syndrome Market to Register Sustainable Growth During the Study Period (2019-2032), Predicts DelveInsight | Key Players - Horizon Therapeutics, Dompe Farmaceutici, MorphoSys, Resolve Therapeutics, Novartis, Johnson & Johnson
Published:
2024-01-16
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-10.78%
|
O:
-1.83%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-10.59%
|
O:
-1.02%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
18.31%
|
O:
0.77%
H:
0.17%
C:
-1.65%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-10.76%
|
O:
0.45%
H:
0.06%
C:
-0.5%
IMAB
|
$1.81
1.12%
1.1%
390K
|
Health Technology
|
-2.69%
|
O:
-1.08%
H:
0.0%
C:
-8.42%
resolve
key
growth
study
market
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Published:
2024-01-02
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-6.94%
|
O:
-0.02%
H:
0.41%
C:
0.41%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
28.79%
|
O:
-0.43%
H:
2.12%
C:
2.03%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-7.05%
|
O:
-0.45%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-16.04%
|
O:
-0.64%
H:
4.97%
C:
4.9%
ibi362
obesity
first
chinese
study
Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published:
2023-12-20
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-3.34%
|
O:
-0.1%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.46%
|
O:
-1.87%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
31.67%
|
O:
0.21%
H:
0.63%
C:
0.1%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-5.45%
|
O:
-0.08%
H:
0.0%
C:
0.0%
cancer
growth
study
market
Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Assesses DelveInsight | Key Players in the Market - Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo
Published:
2023-12-19
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-3.41%
|
O:
-0.39%
H:
1.49%
C:
0.32%
SUPN
|
$28.97
-1.56%
-1.59%
390K
|
Health Technology
|
3.17%
|
O:
-0.11%
H:
0.82%
C:
-2.31%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-5.26%
|
O:
0.21%
H:
0.0%
C:
0.0%
AXSM
|
$69.69
1.28%
1.26%
400K
|
Health Technology
|
-6.82%
|
O:
-0.46%
H:
0.0%
C:
-4.03%
ACAD
|
News
|
$17.2
0.7%
0.7%
1M
|
Health Technology
|
-42.88%
|
O:
-0.17%
H:
0.76%
C:
-3.42%
therapeutics
growth
study
market
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published:
2023-12-13
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-3.35%
|
O:
0.25%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
28.73%
|
O:
1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-4.53%
|
O:
0.0%
H:
0.0%
C:
0.0%
positive
cancer
growth
study
market
Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda
Published:
2023-12-12
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-1.13%
|
O:
-0.06%
H:
2.36%
C:
2.36%
UCBJY
|
$63.31
-4.38%
9.4K
|
Manufacturing
|
53.09%
|
O:
-0.62%
H:
1.01%
C:
1.01%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-6.51%
|
O:
-0.71%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-2.74%
|
O:
-0.27%
H:
2.28%
C:
2.16%
CPRX
|
$15.99
2.9%
2.81%
1.4M
|
Health Technology
|
16.4%
|
O:
-0.37%
H:
5.49%
C:
5.49%
companies
positive
growth
study
market
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published:
2023-12-07
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
0.64%
|
O:
-1.66%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-0.35%
|
O:
-1.19%
H:
0.0%
C:
0.0%
positive
ongoing
collaboration
study
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published:
2023-12-06
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-1.66%
|
O:
-2.77%
H:
0.49%
C:
0.49%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
28.8%
|
O:
0.99%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-0.95%
|
O:
-0.6%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-3.83%
|
O:
-0.2%
H:
1.7%
C:
1.3%
rient-16
treatment
results
study
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight
Published:
2023-11-21
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-0.36%
|
O:
-0.74%
H:
0.71%
C:
0.71%
RCUS
4
|
$14.84
-6.49%
0.0%
790K
|
Health Technology
|
7.46%
|
O:
1.88%
H:
0.92%
C:
-1.42%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-1.03%
|
O:
-0.34%
H:
0.0%
C:
0.0%
drug
cancer
treatment
show
growth
study
market
Type 1 Diabetes Market to Accelerate Substantially During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici
Published:
2023-11-15
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
4.94%
|
O:
3.37%
H:
1.29%
C:
1.29%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
29.14%
|
O:
2.62%
H:
0.67%
C:
0.58%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
22.97%
|
O:
-3.12%
H:
0.61%
C:
-0.46%
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
12.53%
|
O:
0.4%
H:
0.38%
C:
-2.2%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
1.65%
|
O:
1.54%
H:
0.0%
C:
0.0%
companies
diabetes
study
market
More than two in three people with diabetes already have complications at diagnosis, International Diabetes Federation study finds
Published:
2023-11-14
(Crawled : 00:00)
- prnewswire.com
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
1.61%
|
O:
0.68%
H:
0.0%
C:
0.0%
international
diabetes
study
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
Published:
2023-11-06
(Crawled : 21:00)
- prnewswire.com
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
0.95%
|
O:
-1.32%
H:
0.0%
C:
0.0%
TXG
|
$29.12
-5.46%
-5.77%
2.9M
|
Health Technology
|
-24.55%
|
O:
-0.98%
H:
3.21%
C:
1.96%
genomics
study
Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) | DelveInsight
Published:
2023-10-31
(Crawled : 21:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
3.73%
|
O:
0.94%
H:
2.55%
C:
2.55%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-26.4%
|
O:
-4.18%
H:
0.49%
C:
-0.02%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
32.11%
|
O:
-2.76%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
1.21%
|
O:
0.18%
H:
0.0%
C:
0.0%
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
|
-12.34%
|
O:
-0.2%
H:
3.45%
C:
1.37%
CALT
|
$18.8
5.62%
5.32%
6.8K
|
Health Technology
|
9.2%
|
O:
-2.27%
H:
2.01%
C:
0.44%
study
market
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.